Latest New Zealand News

ABx Group has lodged a prospectus for a fully underwritten $2 million share purchase plan, forming part of a broader $4.1 million capital raising for its Deep Leads rare earths project and ALCORE pilot plant. The offer gives eligible shareholders discounted shares and options, but leaves the final price unknown until after applications close and remains subject to shareholder approval.

Minerals 260 has opened a non-underwritten share purchase plan targeting up to $30 million at $0.88 a share, the same price paid by institutional investors in its $250 million placement. The broader funding package is intended to move the Bullabulling Gold Project towards construction.

Barramundi Limited (NZX:BRM) has reported the worst performance in its 20-year history, with a NZ$42.9 million net loss and a 17.0% fall in gross portfolio performance. The board is reviewing Fisher Funds’ management performance just weeks before its five-year agreement comes up for renewal.

Perennial Better Future Active ETF will be voluntarily wound up after a $2.601 million loss and a sharp contraction in its unitholder base. The fund’s Responsible Entity says it is unlikely to achieve the scale needed to operate economically, with the process expected to finish in financial year 2027.

Bremworth has restored internal yarn production, cut costs and improved its inventory profile, but FY26 still ended with an NZ$11.4 million loss. The company now enters FY27 under new ownership and board dynamics, with positive operating cash flow still to be achieved.

Flynn Gold has lodged a prospectus for a one-for-three renounceable rights issue priced at 1.5 cents, offering shareholders a heavily discounted entry point alongside free options. The partially underwritten raise is intended to fund Golden Ridge drilling, a maiden Firetower resource estimate and working capital.

Memphasys says it has identified a potential FDA 510(k) pathway for its Felix sperm separation system, replacing the more complex De Novo route previously contemplated. The company will seek FDA feedback before targeting a formal submission in the first quarter of 2027, while keeping commercial execution focused on existing markets.

Big River Industries delivered a stronger FY26 despite subdued residential construction, lifting underlying EBITDA 8.4% and reducing gearing after its Johns Building Supplies acquisition. The company is targeting double-digit underlying EBITDA growth in FY27, while its strategic options review remains unresolved.

SkinKandy Limited (ASX:SK1) exceeded its IPO forecasts in FY26, with pro forma revenue rising 29% to A$90.2 million and pro forma NPAT climbing 41% to A$9.0 million. The newly listed retailer enters FY27 with 115 stores, 11 approved leases and plans for potential expansion into South Africa and the United States.

GWA Group delivered its third consecutive year of volume growth in FY26, lifting revenue, normalised EBIT and its fully franked dividend despite weak housing and renovation conditions. The trade-off was a sharp decline in operating cash flow and higher net debt following inventory purchases and a $25 million share buyback.

Me Today reported a NZ$2.66 million FY26 profit, but the result was dominated by a NZ$4.12 million gain from losing control of King Honey. The remaining business grew revenue and improved its operating loss, yet continued to consume cash and will rely on October warrant funding.

Nick Scali delivered a sharp recovery in FY26 earnings, with net profit rising 31.2% to $75.7 million as gross margins widened and the UK loss narrowed. The furniture retailer is entering FY27 with a larger showroom network, a new distribution centre and four further ANZ openings planned.